CCR4 and adult T-cell leukemia/lymphoma: For example, the CC chemokine receptor 4 (CCR4)-targeting glyco-engineered antibody, mogamulizumab, has enhanced ADCC with no known explanation, but has recently been approved in Japan for use in patients with relapsed and refractory CCR4-positive adult T cell leukemia/lymphoma35.